Future needs of young people receiving botulinum toxin A in paediatric rehabilitation services of New South Wales: focus on transition

Simon P Paget; Anne de Groot; Kerry Hanns; Heather Burnett; Jane Ho

doi:10.1111/imj.14989

Future needs of young people receiving botulinum toxin A in paediatric rehabilitation services of New South Wales: focus on transition

Intern Med J. 2020 Sep;50(9):1138-1141. doi: 10.1111/imj.14989.

Authors

Simon P Paget^{1

2}, Anne de Groot^{1

3}, Kerry Hanns⁴, Heather Burnett⁵, Jane Ho^{2

3}

Affiliations

¹ Kids Rehab, The Children's Hospital at Westmead, Australia.
² Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney, Australia.
³ Trapeze, Sydney Children's Hospitals Network, Australia.
⁴ Rehab2Kids, Sydney Children's Hospital, Australia.
⁵ HNE Kids Rehab, John Hunter Children's Hospital, Sydney, New South Wales, Australia.

PMID: 32929823
DOI: 10.1111/imj.14989

Abstract

Young people (YP) with neurological disabilities such as cerebral palsy are increasingly living into adulthood and require healthcare transition for services including for botulinum toxin A (BoNT-A). We analysed medical records in the three children's hospitals in New South Wales (NSW) and identified 253 YP who are expected to transition from paediatric to adult BoNT-A services in NSW and Australian Capital Territory during 2018-2023. A substantial proportion of these YP have additional needs that will require paediatric and adult health services to work together to improve their life-long health outcomes.

Keywords: botulinum toxin; cerebral palsy; healthcare transition.

MeSH terms

Adolescent
Adult
Australia
Australian Capital Territory
Botulinum Toxins, Type A*
Cerebral Palsy* / drug therapy
Cerebral Palsy* / epidemiology
Child
Humans
New South Wales / epidemiology
Transition to Adult Care*

Substances

Botulinum Toxins, Type A

Grants and funding

Agency for Clinical Innovation, NSW Ministry of Health/International